In-Vitro Diagnostic Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and by End User (Stand Alone Laboratory, Hospitals, Academics and Medical Schools, Point of Care Testing, and Other End Users) – Global Opportunity Analysis and Industry Forecast, 2024–2030

In-Vitro Diagnostics (IVD) Market

Industry:  Life Sciences & Healthcare | Publish Date: Jun 2024 | No of Pages:  490 | No. Tables:  340 | No. Figures:  297

In-vitro Diagnostic Market Overview

The global In-Vitro Diagnostic (IVD) Market size was valued at USD 83.63 billion in 2023 and is predicted to reach USD 114.02 billion by 2030, with a CAGR of 4.2% from 2024 to 2030. The IVD market includes a range of medical devices and tests used to diagnose diseases or conditions from samples such as blood, urine, or tissue, without the need for invasive procedures. This market includes various test types such as clinical chemistry, molecular diagnostics, immunoassays, hematology, microbiology, and coagulation, utilizing technologies such as PCR, next-generation sequencing, microarrays, mass spectrometry, and immunoassays.

IVDs are crucial for disease diagnosis, monitoring chronic conditions, guiding treatment decisions, and disease screening in areas such as oncology, infectious diseases, cardiology, diabetes, and genetic disorders. These diagnostics are employed in diverse healthcare settings, including hospitals, laboratories, and outpatient clinics, playing a vital role in modern healthcare by enabling accurate and timely medical decisions.

Increasing Prevalence of Chronic and Infectious Diseases Boost the Market Growth

The rising prevalence of chronic and infectious diseases, including cancer, cardiovascular diseases, diabetes, and various infections is primarily propelling the demand for diagnostic tests in the IVD market. As healthcare systems strive to address these escalating health challenges, there is a growing emphasis on early detection, disease monitoring, and personalized treatment strategies.

According to the World Health Organization, Noncommunicable diseases (NCDs) are responsible for an alarming 41 million deaths annually, comprising approximately 74% of all global fatalities. Among NCDs, cardiovascular diseases lead the mortality statistics, claiming 17.9 million lives each year, followed by cancers at 9.3 million, chronic respiratory diseases at 4.1 million, and diabetes at 2.0 million.

In-vitro diagnostics, with their ability to provide rapid and accurate diagnostic information, are indispensable in facilitating proactive healthcare interventions and improving patient outcomes. Consequently, the market is poised for substantial expansion as healthcare systems worldwide intensify efforts to combat the burgeoning burden of chronic and infectious diseases.

 

Growing Aging Population Drives the Market Growth

The aging population, characterized by its increasing prevalence of age-related diseases and conditions worldwide, serves as a primary factor for the IVD market growth. As the population ages, there is a corresponding increase in the prevalence of age-related diseases and conditions, necessitating more frequent diagnostic testing for early detection, monitoring, and management to prevent further progression and complications.

This demographic shift is clearly observable from the projected rise of individuals aged 65 years and older, expected to more than double from 761 million in 2021 to 1.6 billion by 2050 worldwide. As a result, healthcare providers are confronted with the increasing task of meeting the changing healthcare requirements of elderly individuals, driving the need for advanced diagnostic solutions.

Moreover, the specific healthcare demands of the aging population emphasize the necessity for precise diagnostic technologies tailored to individual needs. Therefore, the aging demographic plays a pivotal role in shaping the growth and development of the market, influencing its future trajectory. 

High Costs Associated with R&D and Regulatory Approval Hinders the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the in-vitro diagnostic market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.

Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion, which in turn hinders the industry growth.

Introduction of Point-Of-Care Testing Solutions in IVD Creates Ample Opportunities for the Market

Point-of-care testing (POCT) is poised to be a significant opportunity for the IVD market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

POCT technologies offers rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more. That’s why healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

By Type, Reagents Holds the Dominant Share in the In-vitro Diagnostic Market

Reagents hold the dominant share of approximately 60% in the type segment of the IVD market as these are essential components used in various diagnostic tests to detect specific biomarkers or substances indicative of diseases or health conditions. They play a fundamental role in facilitating accurate and reliable test results, thus being indispensable in the diagnostic process.

Additionally, reagents are versatile and can be tailored to accommodate different testing methodologies and platforms, making them widely applicable across a range of diagnostic techniques and technologies. Moreover, the continuous demand for diagnostic testing, driven by factors such as the increasing prevalence of chronic diseases, growing aging population, and expanding healthcare infrastructure globally, further contributes to the dominance of reagents in the in-vitro diagnostic market.

By Application, Gastrointestinal Diseases, Holds the highest CAGR of 6 %

Gastrointestinal diseases boast the highest CAGR of 6%, driven by the widespread prevalence and diversity of conditions such as inflammatory bowel disease (IBD), gastroenteritis, and gastrointestinal cancers. This future growth is also supported by advanced diagnostic techniques including stool analysis, which employs microscopy and biochemical tests to identify infections, inflammation, and malabsorption markers.

Additionally, serological tests such as ELISA and Western blot detect specific antibodies or proteins linked to conditions such as celiac disease or IBD, while PCR assays identify pathogens including Helicobacter pylori and viruses. These sophisticated diagnostic tools enhance the accuracy and management of gastrointestinal disorders, contributing significantly to the IVD market expansion.

 

North America Region Dominates the In-vitro Diagnostic Market 

The North America region holds around 40% of the global IVD market share due to the rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer. According to the National Association of Chronic Disease Directors, cardiovascular diseases account for one out of every three deaths in the U.S., totaling 859,000 deaths annually. This significant burden has increased the demand for IVDs, which are crucial for diagnosing, monitoring, and managing chronic diseases. 

Innovative technologies and advancements in diagnostic techniques enable healthcare providers to better identify at-risk individuals, tailor treatment plans to individual needs, and improve patient outcomes. Moreover, the presence of prominent companies such as Bio-Rad Laboratories Inc., Becton, Dickinson and Company, Abbott Laboratories, and Quest Diagnostics drives market growth through innovation, R&D activities, and collaborations. 

For example, in January 2023, Bio-Rad Laboratories Inc. introduced the CFX Opus 96 Dx Real-Time PCR System, a product approved by the U.S. Food and Drug Administration (FDA) and compliant with European Union regulations for in-vitro diagnostic medical devices. This system features a user-friendly interface and intuitive software, which simplifies operation and minimizes training requirements for lab staff, which in turn boost the market growth. 

Asia-Pacific is Expected to Show Steady Growth in the In-vitro Diagnostic Market Share with a CAGR of 5.4%

The Asia-Pacific region is anticipated to experience the highest growth rate primarily due to rapidly aging population. As individuals age, their susceptibility to chronic diseases such as cardiovascular conditions, diabetes, and neurological disorders increases, necessitating early detection, accurate diagnosis, and personalized treatment options.

For instance, Japan serves as a prominent example, where over 10% of the population is currently aged 80 or above, and approximately one-third, totaling an estimated 36.23 million people, are aged over 65. This demographic shift not only signifies a profound change in population dynamics but also presents complex healthcare challenges that demand innovative diagnostic solutions.

Moreover, the rising prevalence of cancer in the region is a significant driver for the IVD market. As an example, India witnessed approximately 1,461,427 new cancer cases in 2022, highlighting the urgent need for advanced diagnostic technologies. These solutions play a crucial role in enabling precise cancer diagnosis, monitoring disease progression, and customizing personalized treatment strategies.

Additionally, the robust growth of the medical device market is bolstering the expansion of the healthcare sector in Asia-Pacific. As an example, India’s medical device sector is emerging, with substantial growth in exports and investments in healthcare infrastructure and technology. This growth trajectory facilitates the adoption of advanced diagnostic solutions such as IVDs, enhancing the accessibility, affordability, and quality of diagnostic services across the region.

In fiscal year 2021-22, India's medical device exports reached USD 2.9 billion, marking a notable increase of 15.47% compared to the previous fiscal year. The rise of India's medical device sector has led to greater investment in healthcare infrastructure and technology and enables the way for the adoption of advanced diagnostic solutions such as in-vitro diagnostics, supported by growing exports and demand for healthcare products globally.

 

Competitive Landscape

Several market players operating in the in-vitro diagnostic industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

IVD Market

Source: Primary Research, Secondary Research, Next Move Strategy Consulting

Note: In others we have also analysis the companies such as DiaSorin, Ortho Diagnostics, Arkray, and others.

These market players are adopting various strategies, including partnerships, collaborations, mergers, acquisitions, and innovative product launches across various regions to maintain their dominance in the market. These strategies are crucial due to the rapidly evolving technological landscape and the increasing demand for advanced diagnostic solutions.

DATE

COMPANY

RECENT DEVELOPMENTS

 

 

Feb- 2024

BioMerieux

BioMerieux and the Food and Drug Administration initiated a strategic research collaboration to enhance microbial detection tools aimed at combating food-borne pathogens. This partnership focuses on developing innovative projects to improve the detection and characterization systems for pathogens such as Shiga-toxin producing E. coli, Cyclospora cayetanensis, Salmonella spp., and Listeria monocytogenes.

 

 

Feb-2024

Roche Holding AG

Roche partnered with PathAI to create AI-driven companion diagnostic tools that enables comprehensive solution for precision therapeutics. This partnership aims to accelerate the advancement of precision medicine by integrating AI analysis with companion diagnostics, thereby improving patient access to tailored treatments.

 

 

Feb-2024

Sysmex Corporation

Sysmex and Hitachi High-Tech collaborated to develop new genetic testing systems based on capillary electrophoresis sequencers (CE sequencers). The collaboration combines Hitachi High-Tech's CE sequencer technology with Sysmex's know-how in NGS reagent development and analysis technology.

 
 
 

 

Feb-2024

Danaher Corporation

Danaher Corporation collaborated with Cincinnati Children's Hospital Medical Center to improve patient safety in early drug development. The collaboration aims to address a major cause of failure in clinical trials by improving liver organoid technology as a drug toxicity screening solution.

 
 
 

 

Jan-2024

Becton, Dickinson and Company

BD partnered with Techcyte, an artificial intelligence (AI)-based digital diagnostics company, to develop an AI-based algorithm for a digital cervical cytology system. This system aims to assist cytotechnologists and pathologists in identifying signs of cervical cancer and precancerous lesions effectively through whole-slide imaging.

 

Dec-2023

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific lauched new sample preparation solutions to streamline and automate respiratory diagnostic testing. These solutions aim to improve preanalytical workflows for clinical laboratories and provide IVD and IVD-R approved automated sample preparation solutions to laboratories.

 

Nov- 2023

Roche Holding AG

Roche launched the LightCycler PRO System, a next-generation qPCR technology designed to advance clinical diagnostics and research. This innovative system aims to enhance personalized healthcare, support outbreak readiness, and provide agility and flexibility for translational research and diagnostics.

 

July-2023

Siemens Healthineers AG

Siemens Healthineers launched the Atellica CI Analyzer, a compact testing system designed for immunoassay and clinical chemistry testing. This new addition to the Atellica in vitro diagnostics portfolio received FDA clearance and is available in many major markets.

 

 

June 2022

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. launched the CFX Opus Deepwell Real-Time PCR Detection System. This system is designed to support researchers in developing nucleic acid detection assays and is the latest addition to the Bio-Rad portfolio of CFX Opus Real-Time PCR instruments.

 

 

In-Vitro Diagnostic Market Key Segments

By Type

  • Reagents

  • Instruments

  • Software & Services

By Technique

  • Immunodiagnostics

    • Enzyme-Linked Immunosorbent Assay (ELISA)

    • Rapid Tests

    • Chemiluminescence Immunoassay (CLIA)

    • Enzyme-linked Immunosorbent spot (ELISpot)

    • Radioimmunoassay (RIA)

    • Western Blot

  • Hematology

  • Molecular Diagnostics

    • PCR

    • INAAT 

    • Hybridization 

    • DNA diagnostics 

    • Microarray 

    • Other Molecular Diagnostics

  • Tissue Diagnostics

  • Clinical Chemistry

    • Basic Metabolic Panel 

    • Liver Panel

    • Renal Profile

    • Lipid Profile

    • Thyroid Function Panel 

    • Electrolyte Panel 

    • Speciality Chemicals

  • Other IVD Techniques

By Application

  • Infectious Diseases

  • Cancer

  • Cardiac Diseases

  • Immune System Disorders

  • Nephrological Diseases

  • Gastrointestinal Diseases

  • Others

By End User

  • Stand Alone Laboratory

  • Hospitals

  • Academics and Medical Schools

  • Point of Care Testing

  • Other End Users

By Region        

  • North America    

    • The U.S.

    • Canada

    • Mexico

  • Europe

    • The UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Netherlands

    • Finland

    • Sweden

    • Norway

    • Russia

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Indonesia

    • Singapore

    • Taiwan

    • Thailand

    • Rest of Asia-Pacific

  • RoW

    • Latin America

    • Middle East

    • Africa

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 83.63 Billion

Revenue Forecast in 2030

USD 114.02 Billion

Growth Rate

CAGR of 4.2% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Billion (USD)

Growth Factors

  • Increasing Prevalence of Chronic and Infectious Disease Boost the Market Growth

  • Growing Aging Population Drives the Market Growth

Countries Covered

28

Companies Profiled

15

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

column chart pie chart

Test

1.     INTRODUCTION

1.1.    REPORT DESCRIPTION

1.2.    WHO SHOULD READ THIS REPORT 

1.3.    KEY MARKET SEGMENTS

1.4.    RESEARCH METHODOLOGY

1.4.1         MARKET SIZE ESTIMATION METHODOLOGY

1.4.1.1.      TOP-DOWN AND BOTTOM-UP APPROACH

1.4.1.2.      DEMAND AND SUPPLY SIDE ANALYSIS

1.4.1.3.      MACRO-INDICATOR APPROACH

1.4.2         DATA COLLECTION APPROACH

1.4.2.1.      PRIMARY DATA COLLECTION

1.4.2.2.      SECONDARY DATA COLLECTION

1.4.3         SECONDARY DATA SOURCES

1.4.4         FORECASTING

2.     MARKET DEFINITION & SCOPE

2.1.    DEFINITION

2.2.    SCOPE

3.     IN-VIRTO DIAGNOSTICS MARKET – EXECUTIVE SUMMARY

3.1.    MARKET SNAPSHOT, 2023 - 2030, MILLION USD

4.     MARKET OVERVIEW

4.1.    MARKET DYNAMICS

4.1.1         DRIVERS

4.1.1.1.      INCREASING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASE BOOST THE MARKET GROWTH

4.1.1.2.      THE RISE IN AGING POPULATION CREATES MARKET EXPANSION OF IN VITRO DIAGNOSTICS

4.1.1.3.      ADVANCEMENT IN TECHNOLOGY EXPANDS HORIZONS IN THE IN VITRO MARKET

4.1.2         RESTRAINTS

4.1.2.1.      HIGH COSTS ASSOCIATED WITH RESEARCH, DEVELOPMENT, AND REGULATORY APPROVAL HINDER THE MARKET GROWTH

4.1.3         OPPORTUNITIES

4.1.3.1.      INTRODUCTION OF POINT-OF-CARE TESTING SOLUTIONS IN IVD TO INTRODUCE FUTURE OPPORTUNITY

5.     MARKET SHARE ANALYSIS

5.1.    MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

6.     GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TYPE

6.1.    OVERVIEW

6.2.    REAGENTS

6.2.1         REAGENTS MARKET, BY REGION

6.3.    INSTRUMENTS

6.3.1         INSTRUMENTS  MARKET, BY REGION

6.4.    SOFTWARE AND SERVICES

6.4.1         SOFTWARE AND SERVICES MARKET, BY REGION

7.     GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

7.1.    OVERVIEW

7.2.    IMMUNODIAGNOSTICS

7.2.1         GLOBAL IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

7.2.1.1.      ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY REGION

7.2.1.2.      RAPID TESTS MARKET, BY REGION

7.2.1.3.      CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY REGION

7.2.1.4.      ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY REGION

7.2.1.5.      RADIOIMMUNOASSAY (RIA) MARKET, BY REGION

7.2.1.6.      WESTERN BLOT MARKET, BY REGION

7.2.2         IMMUNODIAGNOSTICS MARKET, BY REGION

7.3.    HEMATOLOGY

7.3.1         HEMATOLOGY MARKET, BY REGION

7.4.    MOLECULAR DIAGNOSTICS

7.4.1         GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

7.4.1.1.      PCR MARKET, BY REGION

7.4.1.2.      INAAT MARKET, BY REGION

7.4.1.3.      HYBRIDIZATION MARKET, BY REGION

7.4.1.4.      DNA DIAGNOSTICS MARKET, BY REGION

7.4.1.5.      MICROARRAY  MARKET, BY REGION

7.4.1.6.      OTHER MOLECULAR DIAGNOSTICS MARKET, BY REGION

7.4.2         MOLECULAR DIAGNOSTICS MARKET, BY REGION

7.5.    TISSUE DISGNOSTICS

7.5.1         TISSUE DISGNOSTICS  MARKET, BY REGION

7.6.    CLINICAL CHEMISTRY

7.6.1         GLOBAL CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

7.6.1.1.      BASIC METABOLIC PANEL  MARKET, BY REGION

7.6.1.2.      LIVER PANEL MARKET, BY REGION

7.6.1.3.      RENAL PROFILE MARKET, BY REGION

7.6.1.4.      LIPID PROFILE MARKET, BY REGION

7.6.1.5.      THYROID FUNCTION PANEL  MARKET, BY REGION

7.6.1.6.      ELECTROLYTE PANEL  MARKET, BY REGION

7.6.1.7.      SPECIALITY CHEMICALS MARKET, BY REGION

7.6.2         CLINICAL CHEMISTRY  MARKET, BY REGION

7.7.    OTHER IVD TECHNIQUES

7.7.1         OTHER IVD TECHNIQUES MARKET, BY REGION

8.     GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

8.1.    OVERVIEW

8.2.    INFECTIOUS DISEASES

8.2.1         INFECTIOUS DISEASES  MARKET, BY REGION

8.3.    CANCER

8.3.1         CANCER  MARKET, BY REGION

8.4.    CARDIAC DISEASES

8.4.1         CARDIAC DISEASES  MARKET, BY REGION

8.5.    IMMUNE SYSTEM DISORDERS

8.5.1         IMMUNE SYSTEM DISORDERS MARKET, BY REGION

8.6.    NEPHROLOGICAL DISEASES

8.6.1         NEPHROLOGICAL DISEASES MARKET, BY REGION

8.7.    GASTROINTESTINAL DISEASES

8.7.1         GASTROINTESTINAL DISEASES MARKET, BY REGION

8.8.    OTHER INDICATIONS

8.8.1         OTHER INDICATIONS MARKET, BY REGION

9.     GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY END-USER

9.1.    OVERVIEW

9.2.    STAND ALONE LABORATORY

9.2.1         STAND ALONE LABORATORY MARKET, BY REGION

9.3.    HOSPITALS

9.3.1         HOSPITALS MARKET, BY REGION

9.4.    ACADEMICS AND MEDICAL SCHOOLS

9.4.1         ACADEMICS AND MEDICAL SCHOOLS MARKET, BY REGION

9.5.    POINT OF CARE TESTING

9.5.1         POINT OF CARE TESTING MARKET, BY REGION

9.6.    OTHER END-USERS

9.6.1         OTHER END-USERS MARKET, BY REGION

10. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY REGION

10.1.  OVERVIEW

10.2.  NORTH AMERICA

10.2.1       NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.2.2       NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.2.1.   NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.2.2.2.   NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.2.3.   NORTH AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.2.3       NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.2.4       NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.2.5       NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY

10.2.5.1.   U.S.

10.2.5.1.1.   U.S. IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.2.5.1.2.   U.S. IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.1.2.1.   U.S. IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.1.2.2.   U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.1.2.3.   U.S. CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.2.5.1.3.   U.S. IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.2.5.1.4.   U.S. IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.2.5.2.   CANADA

10.2.5.2.1.   CANADA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.2.5.2.2.   CANADA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.2.2.1.   CANADA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.2.2.2.   CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.2.2.3.   CANADA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.2.5.2.3.   CANADA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.2.5.2.4.   CANADA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.2.5.3.   MEXICO

10.2.5.3.1.   MEXICO IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.2.5.3.2.   MEXICO IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.3.2.1.   MEXICO IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.3.2.2.   MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.5.3.2.3.   MEXICO CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.2.5.3.3.   MEXICO IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.2.5.3.4.   MEXICO IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.  EUROPE

10.3.1       EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.2       EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.2.1.   EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.2.2.   EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.2.3.   EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.3       EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.4       EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5       EUROPE IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY

10.3.5.1.   UK

10.3.5.1.1.   UK IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.1.2.   UK IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.1.2.1.   UK IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.1.2.2.   UK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.1.2.3.   UK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.1.3.   UK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.1.4.   UK IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.2.   GERMANY

10.3.5.2.1.   GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.2.2.   GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.2.2.1.   GERMANY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.2.2.2.   GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.2.2.3.   GERMANY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.2.3.   GERMANY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.2.4.   GERMANY IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.3.   FRANCE

10.3.5.3.1.   FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.3.2.   FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.3.2.1.   FRANCE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.3.2.2.   FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.3.2.3.   FRANCE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.3.3.   FRANCE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.3.4.   FRANCE IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.4.   ITALY

10.3.5.4.1.   ITALY IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.4.2.   ITALY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.4.2.1.   ITALY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.4.2.2.   ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.4.2.3.   ITALY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.4.3.   ITALY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.4.4.   ITALY IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.5.   SPAIN

10.3.5.5.1.   SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.5.2.   SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.5.2.1.   SPAIN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.5.2.2.   SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.5.2.3.   SPAIN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.5.3.   SPAIN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.5.4.   SPAIN IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.6.   DENMARK

10.3.5.6.1.   DENMARK IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.6.2.   DENMARK IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.6.2.1.   DENMARK IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.6.2.2.   DENMARK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.6.2.3.   DENMARK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.6.3.   DENMARK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.6.4.   DENMARK IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.7.   NETHERLANDS

10.3.5.7.1.   NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.7.2.   NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.7.2.1.   NETHERLANDS IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.7.2.2.   NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.7.2.3.   NETHERLANDS CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.7.3.   NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.7.4.   NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.8.   FINLAND

10.3.5.8.1.   FINLAND IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.8.2.   FINLAND IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.8.2.1.   FINLAND IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.8.2.2.   FINLAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.8.2.3.   FINLAND CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.8.3.   FINLAND IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.8.4.   FINLAND IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.9.   SWEDEN

10.3.5.9.1.   SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.9.2.   SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.9.2.1.   SWEDEN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.9.2.2.   SWEDEN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.9.2.3.   SWEDEN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.9.3.   SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.9.4.   SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.10. NORWAY

10.3.5.10.1.             NORWAY IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.10.2.             NORWAY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.10.2.1................................. NORWAY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.10.2.2........................... NORWAY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.10.2.3.................................. NORWAY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.10.3.             NORWAY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.10.4.             NORWAY IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.11. RUSSIA

10.3.5.11.1.             RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.11.2.             RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.11.2.1.................................. RUSSIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.11.2.2............................. RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.11.2.3.................................... RUSSIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.11.3.             RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.11.4.             RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.3.5.12. REST OF EUROPE

10.3.5.12.1.             REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.5.12.2.             REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.12.2.1...................... REST OF EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.12.2.2................. REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.5.12.2.3....................... REST OF EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.3.5.12.3.             REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.5.12.4.             REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.  ASIA-PACIFIC

10.4.1       ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.2       ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.2.1.   ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.2.2.   ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.2.3.   ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.3       ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.4       ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5       ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY

10.4.5.1.   CHINA

10.4.5.1.1.   CHINA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.1.2.   CHINA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.1.2.1.   CHINA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.1.2.2.   CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.1.2.3.   CHINA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.1.3.   CHINA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.1.4.   CHINA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.2.   JAPAN

10.4.5.2.1.   JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.2.2.   JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.2.2.1.   JAPAN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.2.2.2.   JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.2.2.3.   JAPAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.2.3.   JAPAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.2.4.   JAPAN IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.3.   INDIA

10.4.5.3.1.   INDIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.3.2.   INDIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.3.2.1.   INDIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.3.2.2.   INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.3.2.3.   INDIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.3.3.   INDIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.3.4.   INDIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.4.   SOUTH KOREA

10.4.5.4.1.   SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.4.2.   SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.4.2.1.   SOUTH KOREA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.4.2.2.   SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.4.2.3.   SOUTH KOREA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.4.3.   SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.4.4.   SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.5.   AUSTRALIA

10.4.5.5.1.   AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.5.2.   AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.5.2.1.   AUSTRALIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.5.2.2.   AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.5.2.3.   AUSTRALIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.5.3.   AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.5.4.   AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.6.   INDONESIA

10.4.5.6.1.   INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.6.2.   INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.6.2.1.   INDONESIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.6.2.2.   INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.6.2.3.   INDONESIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.6.3.   INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.6.4.   INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.7.   SINGAPORE

10.4.5.7.1.   SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.7.2.   SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.7.2.1.   SINGAPORE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.7.2.2.   SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.7.2.3.   SINGAPORE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.7.3.   SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.7.4.   SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.8.   TAIWAN

10.4.5.8.1.   TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.8.2.   TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.8.2.1.   TAIWAN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.8.2.2.   TAIWAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.8.2.3.   TAIWAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.8.3.   TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.8.4.   TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.9.   THAILAND

10.4.5.9.1.   THAILAND IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.9.2.   THAILAND IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.9.2.1.   THAILAND IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.9.2.2.   THAILAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.9.2.3.   THAILAND CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.9.3.   THAILAND IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.9.4.   THAILAND IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.4.5.10. REST OF ASIA-PACIFIC

10.4.5.10.1.             REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.5.10.2.             REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.10.2.1............... REST OF ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.10.2.2.......... REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.5.10.2.3................. REST OF ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.4.5.10.3.             REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.5.10.4.             REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.5.  REST OF WORLD

10.5.1       REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.5.2       REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.2.1.   REST OF WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.5.2.2.   REST OF WORLD MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.2.3.   REST OF WORLD CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.5.3       REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.5.4       REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.5.5       REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY

10.5.5.1.   LATIN AMERICA

10.5.5.1.1.   LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.5.5.1.2.   LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.1.2.1.   LATIN AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.1.2.2.   LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.1.2.3.   LATIN AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.5.5.1.3.   LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.5.5.1.4.   LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.5.5.2.   MIDDLE EAST

10.5.5.2.1.   MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.5.5.2.2.   MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.2.2.1.   MIDDLE EAST IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.2.2.2.   MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.2.2.3.   MIDDLE EAST CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.5.5.2.3.   MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.5.5.2.4.   MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY END-USER

10.5.5.3.   AFRICA

10.5.5.3.1.   AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.5.5.3.2.   AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.3.2.1.   AFRICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.3.2.2.   AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

10.5.5.3.2.3.   AFRICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE

10.5.5.3.3.   AFRICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.5.5.3.4.   AFRICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER

11. COMPANY PROFILES

11.1.  BIOMERIEUX

11.1.1       COMPANY OVERVIEW

11.1.2       COMPANY SNAPSHOT

11.1.3       OPERATING BUSINESS SEGMENTS

11.1.4       PRODUCT PORTFOLIO

11.1.5       BUSINESS PERFORMANCE

11.1.6       SALES BY BUSINESS SEGMENT

11.1.7       SALES BY GEOGRAPHIC SEGMENT

11.1.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.1.9       PRIMARY MARKET COMPETITORS

11.2.  ROCHE HOLDING AG

11.2.1       COMPANY OVERVIEW

11.2.2       COMPANY SNAPSHOT

11.2.3       OPERATING BUSINESS SEGMENTS

11.2.4       PRODUCT PORTFOLIO

11.2.5       BUSINESS PERFORMANCE

11.2.6       SALES BY BUSINESS SEGMENT

11.2.7       SALES BY GEOGRAPHIC SEGMENT

11.2.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.2.9       PRIMARY MARKET COMPETITORS

11.3.  BIO-RAD LABORATORIES, INC.

11.3.1       COMPANY OVERVIEW

11.3.2       COMPANY SNAPSHOT

11.3.3       OPERATING BUSINESS SEGMENTS

11.3.4       PRODUCT PORTFOLIO

11.3.5       BUSINESS PERFORMANCE

11.3.6       SALES BY BUSINESS SEGMENT

11.3.7       SALES BY GEOGRAPHIC SEGMENT

11.3.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.3.9       PRIMARY MARKET COMPETITORS

11.4.  BECTON, DICKINSON AND COMPANY

11.4.1       COMPANY OVERVIEW

11.4.2       COMPANY SNAPSHOT

11.4.3       OPERATING BUSINESS SEGMENTS

11.4.4       PRODUCT PORTFOLIO

11.4.5       BUSINESS PERFORMANCE

11.4.6       SALES BY BUSINESS SEGMENT

11.4.7       SALES BY GEOGRAPHIC SEGMENT

11.4.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.4.9       PRIMARY MARKET COMPETITORS

11.5.  SIEMENS HEALTHINEERS AG

11.5.1       COMPANY OVERVIEW

11.5.2       COMPANY SNAPSHOT

11.5.3       OPERATING BUSINESS SEGMENTS

11.5.4       PRODUCT PORTFOLIO

11.5.5       BUSINESS PERFORMANCE

11.5.6       SALES BY BUSINESS SEGMENT

11.5.7       SALES BY GEOGRAPHIC SEGMENT

11.5.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.5.9       PRIMARY MARKET COMPETITORS

11.6.  SYSMEX CORPORATION

11.6.1       COMPANY OVERVIEW

11.6.2       COMPANY SNAPSHOT

11.6.3       OPERATING BUSINESS SEGMENTS

11.6.4       PRODUCT PORTFOLIO

11.6.5       BUSINESS PERFORMANCE

11.6.6       SALES BY BUSINESS SEGMENT

11.6.7       SALES BY GEOGRAPHIC SEGMENT

11.6.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.6.9       PRIMARY MARKET COMPETITORS

11.7.  THERMO FISHER SCIENTIFIC INC.

11.7.1       COMPANY OVERVIEW

11.7.2       COMPANY SNAPSHOT

11.7.3       OPERATING BUSINESS SEGMENTS

11.7.4       PRODUCT PORTFOLIO

11.7.5       BUSINESS PERFORMANCE

11.7.6       SALES BY BUSINESS SEGMENT

11.7.7       SALES BY GEOGRAPHIC SEGMENT

11.7.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.7.9       PRIMARY MARKET COMPETITORS

11.8.  ABBOTT LABORATORIES

11.8.1       COMPANY OVERVIEW

11.8.2       COMPANY SNAPSHOT

11.8.3       OPERATING BUSINESS SEGMENTS

11.8.4       PRODUCT PORTFOLIO

11.8.5       BUSINESS PERFORMANCE

11.8.6       SALES BY BUSINESS SEGMENT

11.8.7       SALES BY GEOGRAPHIC SEGMENT

11.8.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.8.9       PRIMARY MARKET COMPETITORS

11.9.  QIAGEN N.V.

11.9.1       COMPANY OVERVIEW

11.9.2       COMPANY SNAPSHOT

11.9.3       OPERATING BUSINESS SEGMENTS

11.9.4       PRODUCT PORTFOLIO

11.9.5       BUSINESS PERFORMANCE

11.9.6       SALES BY BUSINESS SEGMENT

11.9.7       SALES BY GEOGRAPHIC SEGMENT

11.9.8       KEY STRATEGIC MOVES & DEVELOPMENTS

11.9.9       PRIMARY MARKET COMPETITORS

11.10. DANAHER CORPORATION

11.10.1    COMPANY OVERVIEW

11.10.2    COMPANY SNAPSHOT

11.10.3    OPERATING BUSINESS SEGMENTS

11.10.4    PRODUCT PORTFOLIO

11.10.5    BUSINESS PERFORMANCE

11.10.6    SALES BY BUSINESS SEGMENT

11.10.7    SALES BY GEOGRAPHIC SEGMENT

11.10.8    KEY STRATEGIC MOVES & DEVELOPMENTS

11.10.9    PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH

TABLE 2. SECONDARY DATA SOURCES

TABLE 3. OVERVIEW OF THE SCOPE

TABLE 4. INCLUSIONS AND EXCLUSIONS

TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS, BY TYPE, 2023-2030, MILLION USD

TABLE 6. REAGENTS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 7. INSTRUMENTS  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 8. SOFTWARE AND SERVICES MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 10. GLOBAL IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 12. RAPID TESTS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 15. RADIOIMMUNOASSAY (RIA) MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 16. WESTERN BLOT MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 17. IMMUNODIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 18. HEMATOLOGY MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 20. PCR MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 21. INAAT MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 22. HYBRIDIZATION MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 23. DNA DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 24. MICROARRAY  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 25. OTHER MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 26. MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 27. TISSUE DISGNOSTICS  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 28. GLOBAL CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 29. BASIC METABOLIC PANEL  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 30. LIVER PANEL MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 31. RENAL PROFILE MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 32. LIPID PROFILE MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 33. THYROID FUNCTION PANEL  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 34. ELECTROLYTE PANEL  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 35. SPECIALITY CHEMICALS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 36. CLINICAL CHEMISTRY  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 37. OTHER IVD TECHNIQUES MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 39. INFECTIOUS DISEASES  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 40. CANCER  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 41. CARDIAC DISEASES  MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 42. IMMUNE SYSTEM DISORDERS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 43. NEPHROLOGICAL DISEASES MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 44. GASTROINTESTINAL DISEASES MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 45. OTHER INDICATIONS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 47. STAND ALONE LABORATORY MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 48. HOSPITALS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 49. ACADEMICS AND MEDICAL SCHOOLS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 50. POINT OF CARE TESTING MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 51. OTHER END-USERS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

TABLE 53. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 54. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 55. NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 56. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 57. NORTH AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 58. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 59. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 60. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

TABLE 61. U.S. IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 62. U.S. IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 63. U.S. IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 64. U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 65. U.S. CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 66. U.S. IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 67. U.S. IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 68. CANADA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 69. CANADA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 70. CANADA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 71. CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 72. CANADA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 73. CANADA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 74. CANADA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 75. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 76. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 77. MEXICO IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 78. MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 79. MEXICO CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 80. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 81. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 82. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 83. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 84. EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 85. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 86. EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 87. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 88. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 89. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

TABLE 90. UK IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 91. UK IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 92. UK IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 93. UK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 94. UK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 95. UK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 96. UK IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 97. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 98. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 99. GERMANY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 100. GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 101. GERMANY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 102. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 103. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 104. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 105. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 106. FRANCE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 107. FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 108. FRANCE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 109. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 110. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 111. ITALY IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 112. ITALY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 113. ITALY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 114. ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 115. ITALY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 116. ITALY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 117. ITALY IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 118. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 119. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 120. SPAIN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 121. SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 122. SPAIN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 123. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 124. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 125. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 126. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 127. DENMARK IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 128. DENMARK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 129. DENMARK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 130. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 131. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 132. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 133. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 134. NETHERLANDS IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 135. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 136. NETHERLANDS CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 137. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 138. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 139. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 140. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 141. FINLAND IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 142. FINLAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 143. FINLAND CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 144. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 145. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 146. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 147. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 148. SWEDEN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 149. SWEDEN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 150. SWEDEN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 151. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 152. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 153. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 154. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 155. NORWAY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 156. NORWAY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 157. NORWAY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 158. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 159. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 160. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 161. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 162. RUSSIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 163. RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 164. RUSSIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 165. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 166. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 167. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 168. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 169. REST OF EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 170. REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 171. REST OF EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 172. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 173. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 174. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 175. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 176. ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 177. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 178. ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 179. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 180. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 181. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

TABLE 182. CHINA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 183. CHINA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 184. CHINA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 185. CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 186. CHINA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 187. CHINA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 188. CHINA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 189. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 190. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 191. JAPAN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 192. JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 193. JAPAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 194. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 195. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 196. INDIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 197. INDIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 198. INDIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 199. INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 200. INDIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 201. INDIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 202. INDIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 203. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 204. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 205. SOUTH KOREA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 206. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 207. SOUTH KOREA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 208. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 209. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 210. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 211. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 212. AUSTRALIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 213. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 214. AUSTRALIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 215. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 216. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 217. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 218. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 219. INDONESIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 220. INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 221. INDONESIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 222. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 223. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 224. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 225. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 226. SINGAPORE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 227. SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 228. SINGAPORE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 229. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 230. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 231. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 232. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 233. TAIWAN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 234. TAIWAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 235. TAIWAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 236. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 237. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 238. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 239. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 240. THAILAND IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 241. THAILAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 242. THAILAND CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 243. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 244. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 245. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 246. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 247. REST OF ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 248. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 249. REST OF ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 250. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 251. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 252. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 253. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 254. REST OF WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 255. REST OF WORLD MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 256. REST OF WORLD CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 257. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 258. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 259. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

TABLE 260. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 261. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 262. LATIN AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 263. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 264. LATIN AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 265. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 266. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 267. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 268. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 269. MIDDLE EAST IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 270. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 271. MIDDLE EAST CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 272. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 273. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 274. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

TABLE 275. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 276. AFRICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 277. AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 278. AFRICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

TABLE 279. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

TABLE 280. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

TABLE 281. BIOMERIEUX: COMPANY SNAPSHOT

TABLE 282. BIOMERIEUX: OPERATING SEGMENTS

TABLE 283. BIOMERIEUX: PRODUCT PORTFOLIO

TABLE 284. BIOMERIEUX: BUSINESS SEGMENT

TABLE 285. BIOMERIEUX: GEOGRAPHIC SEGMENT

TABLE 286. BIOMERIEUX: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 287. ROCHE HOLDING AG: COMPANY SNAPSHOT

TABLE 288. ROCHE HOLDING AG: OPERATING SEGMENTS

TABLE 289. ROCHE HOLDING AG: PRODUCT PORTFOLIO

TABLE 290. ROCHE HOLDING AG: BUSINESS SEGMENT

TABLE 291. ROCHE HOLDING AG: GEOGRAPHIC SEGMENT

TABLE 292. BIOMERIEUX: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 293. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 294. BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS

TABLE 295. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 296. BIO-RAD LABORATORIES, INC.: BUSINESS SEGMENT

TABLE 297. BIO-RAD LABORATORIES, INC.: GEOGRAPHIC SEGMENT

TABLE 298. BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 299. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

TABLE 300. BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS

TABLE 301. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 302. BECTON, DICKINSON AND COMPANY: BUSINESS SEGMENT

TABLE 303. BECTON, DICKINSON AND COMPANY: GEOGRAPHIC SEGMENT

TABLE 304. BECTON, DICKINSON AND COMPANY: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 305. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT

TABLE 306. SIEMENS HEALTHINEERS AG: OPERATING SEGMENTS

TABLE 307. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

TABLE 308. SIEMENS HEALTHINEERS AG: BUSINESS SEGMENT

TABLE 309. SIEMENS HEALTHINEERS AG: GEOGRAPHIC SEGMENT

TABLE 310. SIEMENS HEALTHINEERS AG: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 311. SYSMEX CORPORATION: COMPANY SNAPSHOT

TABLE 312. SYSMEX CORPORATION: OPERATING SEGMENTS

TABLE 313. SYSMEX CORPORATION: PRODUCT PORTFOLIO

TABLE 314. SYSMEX CORPORATION: BUSINESS SEGMENT

TABLE 315. SYSMEX CORPORATION: GEOGRAPHIC SEGMENT

TABLE 316. SYSMEX CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 317. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 318. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS

TABLE 319. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 320. THERMO FISHER SCIENTIFIC INC.: BUSINESS SEGMENT

TABLE 321. THERMO FISHER SCIENTIFIC INC.: GEOGRAPHIC SEGMENT

TABLE 322. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 323. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 324. ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 325. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 326. ABBOTT LABORATORIES: BUSINESS SEGMENT

TABLE 327. ABBOTT LABORATORIES: GEOGRAPHIC SEGMENT

TABLE 328. ABBOTT LABORATORIES: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 329. QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 330. QIAGEN N.V.: OPERATING SEGMENTS

TABLE 331. QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 332. QIAGEN N.V.: BUSINESS SEGMENT

TABLE 333. QIAGEN N.V.: GEOGRAPHIC SEGMENT

TABLE 334. QIAGEN N.V.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 335. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 336. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 337. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 338. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 339. DANAHER CORPORATION: GEOGRAPHIC SEGMENT

TABLE 340. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

LIST OF FIGURES

FIGURE 1. MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2022

FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 3. REAGENTS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 4. INSTRUMENTS  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 5. SOFTWARE AND SERVICES MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 7. GLOBAL IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 8. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 9. RAPID TESTS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 10. CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 11. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 12. RADIOIMMUNOASSAY (RIA) MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 13. WESTERN BLOT MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 14. IMMUNODIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 15. HEMATOLOGY MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 17. PCR MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 18. INAAT MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 19. HYBRIDIZATION MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 20. DNA DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 21. MICROARRAY  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 22. OTHER MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 23. MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 24. TISSUE DISGNOSTICS  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 25. GLOBAL CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 26. BASIC METABOLIC PANEL  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 27. LIVER PANEL MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 28. RENAL PROFILE MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 29. LIPID PROFILE MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 30. THYROID FUNCTION PANEL  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 31. ELECTROLYTE PANEL  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 32. SPECIALITY CHEMICALS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 33. CLINICAL CHEMISTRY  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 34. OTHER IVD TECHNIQUES MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 35. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 36. INFECTIOUS DISEASES  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 37. CANCER  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 38. CARDIAC DISEASES  MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 39. IMMUNE SYSTEM DISORDERS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 40. NEPHROLOGICAL DISEASES MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 41. GASTROINTESTINAL DISEASES MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 42. OTHER INDICATIONS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 43. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 44. STAND ALONE LABORATORY MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 45. HOSPITALS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 46. ACADEMICS AND MEDICAL SCHOOLS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 47. POINT OF CARE TESTING MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 48. OTHER END-USERS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 49. GLOBAL IN-VITRO DIAGNOSTICS MARKET, BY REGION, 2023-2030, MILLION USD

FIGURE 50. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 51. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 52. NORTH AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 53. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 54. NORTH AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 55. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 56. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 57. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

FIGURE 58. U.S. IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 59. U.S. IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 60. U.S. IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 61. U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 62. U.S. CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 63. U.S. IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 64. U.S. IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 65. CANADA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 66. CANADA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 67. CANADA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 68. CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 69. CANADA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 70. CANADA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 71. CANADA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 72. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 73. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 74. MEXICO IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 75. MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 76. MEXICO CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 77. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 78. MEXICO IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 79. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 80. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 81. EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 82. EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 83. EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 84. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 85. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 86. EUROPE IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

FIGURE 87. UK IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 88. UK IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 89. UK IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 90. UK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 91. UK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 92. UK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 93. UK IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 94. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 95. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 96. GERMANY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 97. GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 98. GERMANY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 99. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 100. GERMANY IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 101. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 102. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 103. FRANCE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 104. FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 105. FRANCE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 106. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 107. FRANCE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 108. ITALY IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 109. ITALY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 110. ITALY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 111. ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 112. ITALY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 113. ITALY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 114. ITALY IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 115. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 116. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 117. SPAIN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 118. SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 119. SPAIN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 120. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 121. SPAIN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 122. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 123. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 124. DENMARK IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 125. DENMARK MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 126. DENMARK CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 127. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 128. DENMARK IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 129. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 130. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 131. NETHERLANDS IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 132. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 133. NETHERLANDS CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 134. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 135. NETHERLANDS IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 136. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 137. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 138. FINLAND IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 139. FINLAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 140. FINLAND CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 141. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 142. FINLAND IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 143. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 144. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 145. SWEDEN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 146. SWEDEN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 147. SWEDEN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 148. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 149. SWEDEN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 150. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 151. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 152. NORWAY IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 153. NORWAY MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 154. NORWAY CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 155. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 156. NORWAY IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 157. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 158. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 159. RUSSIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 160. RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 161. RUSSIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 162. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 163. RUSSIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 164. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 165. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 166. REST OF EUROPE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 167. REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 168. REST OF EUROPE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 169. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 170. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 171. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 172. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 173. ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 174. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 175. ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 176. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 177. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 178. ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

FIGURE 179. CHINA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 180. CHINA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 181. CHINA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 182. CHINA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 183. CHINA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 184. CHINA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 185. CHINA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 186. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 187. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 188. JAPAN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 189. JAPAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 190. JAPAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 191. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 192. JAPAN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 193. INDIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 194. INDIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 195. INDIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 196. INDIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 197. INDIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 198. INDIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 199. INDIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 200. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 201. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 202. SOUTH KOREA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 203. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 204. SOUTH KOREA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 205. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 206. SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 207. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 208. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 209. AUSTRALIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 210. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 211. AUSTRALIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 212. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 213. AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 214. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 215. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 216. INDONESIA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 217. INDONESIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 218. INDONESIA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 219. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 220. INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 221. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 222. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 223. SINGAPORE IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 224. SINGAPORE MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 225. SINGAPORE CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 226. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 227. SINGAPORE IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 228. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 229. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 230. TAIWAN IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 231. TAIWAN MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 232. TAIWAN CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 233. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 234. TAIWAN IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 235. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 236. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 237. THAILAND IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 238. THAILAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 239. THAILAND CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 240. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 241. THAILAND IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 242. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 243. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 244. REST OF ASIA-PACIFIC IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 245. REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 246. REST OF ASIA-PACIFIC CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 247. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 248. REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 249. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 250. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 251. REST OF WORLD IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 252. REST OF WORLD MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 253. REST OF WORLD CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 254. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 255. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 256. REST OF WORLD IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030, MILLION USD

FIGURE 257. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 258. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 259. LATIN AMERICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 260. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 261. LATIN AMERICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 262. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 263. LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 264. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 265. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 266. MIDDLE EAST IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 267. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 268. MIDDLE EAST CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 269. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 270. MIDDLE EAST IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 271. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE, 2023-2030, MILLION USD

FIGURE 272. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 273. AFRICA IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 274. AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 275. AFRICA CLINICAL CHEMISTRY  MARKET, BY TECHNIQUE, 2023-2030, MILLION USD

FIGURE 276. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030, MILLION USD

FIGURE 277. AFRICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER, 2023-2030, MILLION USD

FIGURE 278. BIOMERIEUX: NET SALES, 2021–2023 ($MILLION)

FIGURE 279. BIOMERIEUX: PRIMARY MARKET COMPETITORS

FIGURE 280. ROCHE HOLDING AG: NET SALES, 2021–2023 ($MILLION)

FIGURE 281. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS

FIGURE 282. BIO-RAD LABORATORIES, INC.: NET SALES, 2021–2023 ($MILLION)

FIGURE 283. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 284. BECTON, DICKINSON AND COMPANY: NET SALES, 2021–2023 ($MILLION)

FIGURE 285. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 286. SIEMENS HEALTHINEERS AG: NET SALES, 2021–2023 ($MILLION)

FIGURE 287. SIEMENS HEALTHINEERS: PRIMARY MARKET COMPETITORS

FIGURE 288. SYSMEX CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 289. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 290. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2021–2023 ($MILLION)

FIGURE 291. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS

FIGURE 292. ABBOTT LABORATORIES: NET SALES, 2021–2023 ($MILLION)

FIGURE 293. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 294. QIAGEN N.V.: NET SALES, 2021–2023 ($MILLION)

FIGURE 295. QIAGEN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 296. DANAHER CORPORATION: NET SALES, 2021–2023 ($MILLION)

FIGURE 297. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Roche Holding AG

  • Abbott Laboratories

  • Thermo Fisher Scientific Inc. 

  • Danaher Corporation

  • Becton, Dickinson and Company

  • Siemens Healthineers AG

  • bioMérieux SA

  • Sysmex Corporation

  • QIAGEN N.V.

  • Bio-Rad Laboratories, Inc.


Frequently Asked Questions
What is the estimated revenue of the global in-vitro diagnostic market by the end of 2030?

According to projections from Next Move Strategy Consulting, the global in-vitro diagnostic market is anticipated to reach USD 114.02 billion by 2030.

Which is the dominating region in the in-vitro diagnostic market?

According to Next Move Strategy Consulting, North America is the dominant region in the in-vitro diagnostic market.

What was the market size of the in-vitro diagnostic market in 2023?

As per NMSC, the global in-vitro diagnostic market was valued at USD 83.63 billion in 2023.

What are the top companies operating in the in-vitro diagnostic market?

Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, and others are the top players operating in the in-vitro diagnostic market landscape.

Which of the type segment dominates the IVD market?

The reagents segment dominates the IVD market. Reagents are essential for conducting a variety of diagnostic tests and are in constant demand.